诺泰生物: 诺泰生物：2025年半年度业绩预告的自愿性披露公告

Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 300 million yuan and 330 million yuan, representing an increase of 72.84 million yuan to 102.84 million yuan compared to the same period last year, which is a year-on-year increase of 32.06% to 45.27% [1] - The expected net profit after deducting non-recurring gains and losses is also projected to be between 300 million yuan and 330 million yuan, with similar growth compared to the previous year [1] Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 227.16 million yuan, and the net profit after deducting non-recurring gains and losses was 229.39 million yuan, with a basic earnings per share of 1.06 yuan [1] Reasons for Performance Change - The company emphasizes a business philosophy of "time-leading, technology-leading" and leverages its competitive advantages in interdisciplinary collaboration and an international business development team to continuously expand its high-quality customer base, resulting in significant growth in sales revenue of peptide raw materials during the reporting period [1]